Compare RYTM & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | AROC |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | 414 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.5B |
| IPO Year | 2017 | 2007 |
| Metric | RYTM | AROC |
|---|---|---|
| Price | $87.63 | $38.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $131.14 | $40.00 |
| AVG Volume (30 Days) | 713.2K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.32% |
| EPS Growth | 28.34 | ★ 74.29 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $1,489,818,000.00 |
| Revenue This Year | $55.34 | $7.06 |
| Revenue Next Year | $86.06 | $5.27 |
| P/E Ratio | ★ N/A | $91.09 |
| Revenue Growth | N/A | ★ 28.70 |
| 52 Week Low | $58.71 | $21.17 |
| 52 Week High | $122.20 | $40.12 |
| Indicator | RYTM | AROC |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 58.97 |
| Support Level | $87.19 | $34.30 |
| Resistance Level | $92.17 | $40.12 |
| Average True Range (ATR) | 5.01 | 1.41 |
| MACD | 0.14 | -0.12 |
| Stochastic Oscillator | 41.38 | 62.21 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.